Mutations, in whom rituximab seems to get little additional value.fifty nine Other genomic subgroups, including patients with BIRC3 gene in patients relapsing after treatment method Together with the BCL2 antagonist venetoclax. 66 Resistance to those agents is linked to these mutations in about 70% of cases, Though they are usually https://terryi433wla0.wikidirective.com/user